^
Association details:
| Biomarker: | FGFR2 rearrangement |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | gunagratinib (ICP-192) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.
Published date:
01/17/2023
Excerpt:
Among the 17 patients who have completed at least one tumor assessment, 9 patients had confirmed partial response (PR) and 7 patients had stable disease (SD). The ORR was 52.9% (9/17). The disease control rate (DCR) was 94.1% (16/17). The median progression free survival (mPFS) was 6.93 months (95% CI, 5.42–not reached) (not mature at cutoff)...The study data demonstrated that gunagratinib is safe and well-tolerated in previously treated patients with locally advanced or metastatic CCA harboring FGFR2 gene fusions or rearrangements.
DOI:
https://meetings.asco.org/abstracts-presentations/215655
Trial ID:
